Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will investigate the safety and efficacy of a Tyrosine Kinase Inhibitor (TKI) called Nilotinib BE (bioequivalent) in individuals with Early Alzheimer\'s disease (EAD). This is a multi-center double blinded, Phase 3 study, that will enroll patients for three years in approximately 50 centers nationwide. The total duration of the study will be for five years.
Epistemonikos ID: 3b02b8c434faaab434ba03219d944cdfc07ecb9b
First added on: May 09, 2024